Skip to main content
Erschienen in: Critical Care 6/2013

01.12.2013 | Commentary

BTLA as a biomarker and mediator of sepsis-induced immunosuppression

verfasst von: Edward R Sherwood, Richard S Hotchkiss

Erschienen in: Critical Care | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Recent research indicates that T-lymphocyte dysfunction may contribute to sepsis-associated morbidity and mortality. B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor expressed by T lymphocytes and B lymphocytes that is important in regulating lymphocyte activation during inflammation and infection. Shubin and colleagues report that higher mean BTLA expression in critically ill patients may have value in identifying patients with infection. Further studies provide evidence that BTLA activation contributes to T-lymphocyte apoptosis during sepsis. Although this study will require follow-up and further investigation, the results advance current knowledge regarding potential mechanisms underlying sepsis-induced immunosuppression and identify BTLA as a candidate biomarker and mediator of T-cell dysfunction during sepsis.
Literatur
1.
Zurück zum Zitat Shubin NJ, Monaghan SF, Heffernan DS, Chung CS, Ayala A: B and T lymphocyte attenuator expression on CD4 + T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care 2013, 17: 276.CrossRef Shubin NJ, Monaghan SF, Heffernan DS, Chung CS, Ayala A: B and T lymphocyte attenuator expression on CD4 + T-cells associates with sepsis and subsequent infections in ICU patients. Crit Care 2013, 17: 276.CrossRef
3.
Zurück zum Zitat Steinberg MW, Cheung TC, Ware CF: The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev 2011, 244: 169-187. 10.1111/j.1600-065X.2011.01064.xPubMedCentralCrossRefPubMed Steinberg MW, Cheung TC, Ware CF: The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev 2011, 244: 169-187. 10.1111/j.1600-065X.2011.01064.xPubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, Bauer M, Riedemann NC: The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011, 15: R183. 10.1186/cc10332PubMedCentralCrossRefPubMed Otto GP, Sossdorf M, Claus RA, Rodel J, Menge K, Reinhart K, Bauer M, Riedemann NC: The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011, 15: R183. 10.1186/cc10332PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM: A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012, 16: R112. 10.1186/cc11404PubMedCentralCrossRefPubMed Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM: A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012, 16: R112. 10.1186/cc11404PubMedCentralCrossRefPubMed
6.
Zurück zum Zitat Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Cheron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F: Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15: R99. 10.1186/cc10112PubMedCentralCrossRefPubMed Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C, Cheron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F: Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care 2011, 15: R99. 10.1186/cc10112PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng X: Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care 2011, 15: R70. 10.1186/cc10059PubMedCentralCrossRefPubMed Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng X: Upregulation of programmed death-1 on T cells and programmed death ligand-1 on monocytes in septic shock patients. Crit Care 2011, 15: R70. 10.1186/cc10059PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306: 2594-2605. 10.1001/jama.2011.1829PubMedCentralCrossRefPubMed Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL, Jarman SD 2nd, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM, Hotchkiss RS: Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306: 2594-2605. 10.1001/jama.2011.1829PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13: 260-268. 10.1016/S1473-3099(13)70001-XPubMedCentralCrossRefPubMed Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13: 260-268. 10.1016/S1473-3099(13)70001-XPubMedCentralCrossRefPubMed
10.
Zurück zum Zitat Chang KC, Burnham CA, Compton SM, Rasche DP, Mazuski R, Smcdonough J, Unsinger J, Korman AJ, Green JM, Hotchkiss RS: Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013, 17: R85. 10.1186/cc12711PubMedCentralCrossRefPubMed Chang KC, Burnham CA, Compton SM, Rasche DP, Mazuski R, Smcdonough J, Unsinger J, Korman AJ, Green JM, Hotchkiss RS: Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013, 17: R85. 10.1186/cc12711PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z: PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14: R220. 10.1186/cc9354PubMedCentralCrossRefPubMed Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z: PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14: R220. 10.1186/cc9354PubMedCentralCrossRefPubMed
12.
13.
Zurück zum Zitat Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A: BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 2012, 92: 593-603. 10.1189/jlb.1211641PubMedCentralCrossRefPubMed Shubin NJ, Chung CS, Heffernan DS, Irwin LR, Monaghan SF, Ayala A: BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J Leukoc Biol 2012, 92: 593-603. 10.1189/jlb.1211641PubMedCentralCrossRefPubMed
Metadaten
Titel
BTLA as a biomarker and mediator of sepsis-induced immunosuppression
verfasst von
Edward R Sherwood
Richard S Hotchkiss
Publikationsdatum
01.12.2013
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 6/2013
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc13143

Weitere Artikel der Ausgabe 6/2013

Critical Care 6/2013 Zur Ausgabe

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.